Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8682-8689

  Yanagawa, Takashi ^a,b   Funasaka, Tatsuyoshi ^a   Tsutsumi, Soichi ^b   Hu, Huankai ^a   Watanabe, Hideomi ^b   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCRINE MOTILITY FACTOR; AUTOCRINE MOTILITY FACTOR RECEPTOR; CELL SURFACE RECEPTOR; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCOPROTEIN GP 78; LEUCINE ZIPPER PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE) POLYMERASE FAMILY 14; UBIQUITIN; UNCLASSIFIED DRUG;

ANTIGENICITY; ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DNA LIBRARY; ENDOPLASMIC RETICULUM; ENZYME REGULATION; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; IMMUNOPRECIPITATION; LYSOSOME; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN SECRETION; PROTEIN STABILITY; RNA INTERFERENCE; TWO HYBRID SYSTEM; UBIQUITINATION;

AUTOCRINE MOTILITY FACTOR; BONE NEOPLASMS; COLONIC NEOPLASMS; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; FIBROSARCOMA; GLUCOSE-6-PHOSPHATE ISOMERASE; HT29 CELLS; HUMANS; OSTEOSARCOMA; POLY(ADP-RIBOSE) POLYMERASES;

EID: 34548757447     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1586     Document Type: Article

References (50)

1. Harrison RA. The detection of hexokinase, glucose-phosphate isomerase and phosphoglucomutase activities in polyacrylamide gels after electrophoresis: a novel method using immobilized glucose 6-phosphate dehydrogenase. Anal Biochem 1974;61:500-7.
2. Funasaka T, Haga A, Raz A, Nagase H. Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid. Biochem Biophys Res Commun 2002;293:192-200.
3. Funasaka T, Haga A, Raz A, Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 2001;285:118-28.
4. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996;56:2960-3.
5. Chaput M, Claes V, Portetelle D, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 1988;332:454-5.
6. Xu W, Seiter K, Feldman E, Ahmed T, Chiao JW. The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood 1996;87:4502-6.
7. Yakirevich E, Naot Y. Cloning of a glucose phosphate isomerase/ neuroleukin-like sperm antigen involved in sperm agglutination. Biol Reprod 2000;62:1016-23.
8. Cao MJ, Osatomi K, Matsuda R, Ohkubo M, Hara K, Ishihara T. Purification of a novel serine proteinase inhibitor from the skeletal muscle of white croaker (Argyrosomus argentatus). Biochem Biophys Res Commun 2000;272:485-9.
9. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
10. Takeuchi K, Watanabe H, Takagishi K. Biochemical investigation of cell motile activity in rheumatoid synovial fluid. J Rheumatol 1998;25:9-15.
11. Beutler E, West C, Britton HA, Harris J, Forman L. Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol Dis 1997;23:402-9.
12. Schroter W, Eber SW, Bardosi A, Gahr M, Gabriel M, Sitzmann FC. Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg). Eur J Pediatr 1985;144:301-5.
13. Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-1 melanoma autocrine motility factor and its receptor. Cancer Res 1991;51:3507-11.
14. Baumann M, Brand K. Purification and characterization of phosphohexose isomerase from human gastrointestinal carcinoma and its potential relationship to neuroleukin. Cancer Res 1988;48:7018-21.
15. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E. The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 1990;8:351-6.
16. Filella X, Molina R, Jo J, Mas E, Ballesta AM. Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumour Biol 1991;12:360-7.
17. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N, Raz A. Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. J Biol Chem 2005;280:10419-26.
18. Yanagawa T, Watanabe H, Takeuchi T, Fujimoto S, Kurihara H, Takagishi K. Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-β. Lab Invest 2004;84:513-22.
19. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004;10:7775-84.
20. Shimizu K, Tani M, Watanabe H, et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999;456:295-300.
21. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci U S A 2001;98:14422-7.
22. Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, Weissman AM. The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci U S A 2006;103:341-6.
23. Li G, Zhou X, Zhao G, Schindelin H, Lennarz WJ. Multiple modes of interaction of the deglycosylation enzyme, mouse peptide N-glycanase, with the proteasome. Proc Natl Acad Sci U S A 2005;102:15809-14.
24. Mishra S, Raz A, Murphy LJ. Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function. Cancer Res 2004;64:2516-22.
25. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res 2002;8:3285-9.
26. Cohen S, Knoll BJ, Little JW, Mount DW. Preferential cleavage of phage λ repressor monomers by recA protease. Nature 1981;294:182-4.
27. Colicelli J, Birchmeier C, Michaeli T, O'Neill K, Riggs M, Wigler M. Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci U S A 1989;86:3599-603.
28. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
29. Gracy RW, Tilley BE. Phosphoglucose isomerase of human erythrocytes and cardiac tissue. Methods Enzymol 1975;41:392-400.
30. Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 2003;63:242-9.
31. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000;19:94-102.
32. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001;2:195-201.
33. Aravind L. The WWE domain: a common interaction module in protein ubiquitination and ADP ribosylation. Trends Biochem Sci 2001;26:273-5.
34. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-28.
35. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays 2004;26:882-93.
36. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Perez JM. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 2005;88:143-72.
37. Du L, Zhang X, Han YY, et al. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 2003;278:18426-33.
38. Smith S, de Lange T. Tankyrase promotes telomere elongation in human cells. Curr Biol 2000;10:1299-302.
39. Kaminker PG, Kim SH, Taylor RD, et al. TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J Biol Chem 2001;276:35891-9.
40. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998;282:1484-7.
41. Goenka S, Boothby M. Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc Natl Acad Sci U S A 2006;103:4210-5.
42. Aguiar RC, Takeyama K, He C, Kreinbrink K, Shipp MA. B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem 2005;280:33756-65.
43. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood 2000;96:4328-34.
44. Ciftci O, Ullrich O, Schmidt CA, Diestel A, Hass R. Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after Adriamycin treatment. Blood 2001;97:2830-8.
45. Ullrich O, Grune T. Proteasomal degradation of oxidatively damaged endogenous histones in K562 human leukemic cells. Free Radic Biol Med 2001;31:887-93.
46. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.
47. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
48. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
49. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
50. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272-82.